Cancer Monoclonal Antibodies Market 2025 to 2034
Cancer Monoclonal Antibodies Market 2025 to 2034
Cancer Monoclonal Antibodies Market (By Type: Humanized, Human, Chimeric, Murine; By Application: Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Others; By Monoclonal Antibody Therapies: Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Other Monoclonal Antibody Therapies; By End-User: Hospitals, Research Institutes, Others) Industry Size, Share, Growth, Trends 2025 to 2034.
Customisation Request
Revenue, 2025
USD 125.10 Bn
Forecast Year, 2034
USD 577.26 Bn
CAGR, 2025 - 2034
18.52%
Report Coverage
Worldwide
Published By
Saurabh Bidwai
Reviewed By
Aditi Shivarkar
Reviewed By
Aman Singh
The global cancer monoclonal antibodies market, valued at USD 125.1 billion in 2025, is projected to surge to USD 577.27 billion by 2034, growing at a CAGR of 18.52%, driven by rising oncology prevalence and advancements in targeted therapies.
Cancer Monoclonal Antibodies Market Size Analysis
Cancer Monoclonal Antibodies Market Size By Type 2025 to 2034 (USD Billion)
| Type | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Humanized | 55.83 | 64.83 | 76.31 | 89.38 | 104.27 | 123.30 | 143.74 | 170.35 | 199.90 | 233.71 |
| Human | 31.18 | 36.90 | 44.13 | 51.88 | 61.18 | 72.26 | 86.10 | 101.30 | 119.01 | 139.88 |
| Chimeric | 24.99 | 30.22 | 35.78 | 43.11 | 51.94 | 61.76 | 74.27 | 87.64 | 104.36 | 125.00 |
| Murine | 13.10 | 16.32 | 19.51 | 23.90 | 29.45 | 35.24 | 42.64 | 51.67 | 63.80 | 78.68 |
Cancer Monoclonal Antibodies Market Size By Application 2025 to 2034 (USD Billion)
| Application | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Blood Cancer | 36.76 | 42.90 | 50.54 | 59.06 | 69.37 | 80.54 | 94.03 | 109.62 | 126.73 | 147.94 |
| Breast Cancer | 24.79 | 28.66 | 33.04 | 38.80 | 44.80 | 52.21 | 60.66 | 71.13 | 84.57 | 101.03 |
| Lung Cancer | 19.03 | 22.48 | 26.39 | 30.60 | 37.03 | 44.58 | 52.58 | 60.39 | 70.55 | 83.74 |
| Melanoma | 13.13 | 15.32 | 18.59 | 22.59 | 26.97 | 32.61 | 38.70 | 46.54 | 55.88 | 65.37 |
| Colorectal Cancer | 12.23 | 15.39 | 18.36 | 21.69 | 25.82 | 31.73 | 38.64 | 46.46 | 56.61 | 67.27 |
| Liver Cancer | 6.40 | 7.78 | 9.95 | 12.70 | 14.99 | 18.16 | 22.45 | 28.51 | 34.25 | 43.52 |
| Others | 12.77 | 15.75 | 18.85 | 22.84 | 27.88 | 32.74 | 39.68 | 48.29 | 58.49 | 68.40 |
Cancer Monoclonal Antibodies Market Size By Therapy 2025 to 2034 (USD Billion)
| Therapy | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Bevacizumab (Avastin) | 30.82 | 36.42 | 42.42 | 50.36 | 58.81 | 69.55 | 81.57 | 96.79 | 115.61 | 135.31 |
| Rituximab (Rituxan) | 24.86 | 28.69 | 33.60 | 40.24 | 47.45 | 55.95 | 67.09 | 78.87 | 92.20 | 108.50 |
| Trastuzumab (Herceptin) | 25.31 | 29.99 | 35.15 | 40.98 | 49.08 | 57.68 | 67.69 | 78.90 | 92.00 | 108.24 |
| Cetuximab (Erbitux) | 12.49 | 15.49 | 18.34 | 21.99 | 26.50 | 32.66 | 38.90 | 46.19 | 54.76 | 66.61 |
| Panitumumab (Vectibix) | 13.08 | 15.27 | 19.17 | 22.56 | 27.74 | 32.43 | 39.94 | 48.84 | 57.87 | 70.15 |
| Other Monoclonal Antibody Therapies | 18.54 | 22.42 | 27.05 | 32.14 | 37.26 | 44.29 | 51.53 | 61.36 | 74.63 | 88.46 |
Cancer Monoclonal Antibodies Market Size By End-User 2025 to 2034 (USD Billion)
| End-User | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | 74.62 | 88.33 | 104.44 | 123.25 | 144.64 | 169.79 | 200.51 | 235.95 | 278.59 | 328.35 |
| Research Institutes | 31.02 | 36.63 | 43.61 | 51.91 | 62.43 | 75.15 | 89.05 | 105.14 | 124.39 | 147.68 |
| Others | 19.46 | 23.30 | 27.67 | 33.11 | 39.78 | 47.63 | 57.18 | 69.86 | 84.09 | 101.24 |
Cancer Monoclonal Antibodies Market Size By Region 2025 to 2034 (USD Billion)
| Region | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| North America | 49.34 | 57.19 | 67.17 | 78.15 | 91.87 | 108.53 | 127.31 | 149.03 | 175.07 | 206.07 |
| Europe | 31.30 | 37.50 | 44.01 | 52.10 | 61.46 | 73.33 | 84.78 | 100.48 | 119.49 | 140.85 |
| Asia Pacific | 24.96 | 29.06 | 34.19 | 40.17 | 47.79 | 56.06 | 66.64 | 78.76 | 91.72 | 110.73 |
| Latin America | 12.49 | 15.64 | 19.58 | 23.65 | 28.07 | 33.92 | 41.24 | 50.77 | 61.85 | 73.33 |
| Middle East and Africa | 7.01 | 8.88 | 10.78 | 14.19 | 17.67 | 20.72 | 26.77 | 31.92 | 38.94 | 46.30 |
Cancer Monoclonal Antibodies Market Size to Reach USD 577.26 Billion by 2034
The global cancer monoclonal antibodies market size was calculated at USD 125.1 billion in 2025 and is predicted to attain around USD 577.268 billion by 2034 a CAGR of 18.52%.
Proceed To Buy
Proceed To CheckoutMake Every Move Strategic. Get Insights, Fully Customized
- On-Demand Metrics & KPIs
- Industry-Specific Dashboards
- Quick Turnaround, No Compromises
Quick Contact
- NA : +1 804 441 9344
- APAC : +91 9356 9282 04
- EU : +44 7782 560 738
- sales@precedenceresearch.com
